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The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East (ME) is
among the highest in the world.
The aim of this article is to review the current prevalence of dyslipidaemia and known gaps in its
management in the ME region, and to propose initiatives to address the burden of dyslipidaemia.
Published literature on the epidemiology of dyslipidaemia in the ME region was presented and dis-
cussed at an expert meeting that provided the basis of this review article.
The high prevalence of metabolic syndrome, diabetes, familial hypercholesterolaemia (FH) and
consanguineous marriages, in the ME region, results in a pattern of dyslipidaemia (low high-density
lipoprotein cholesterol and high triglycerides) that is different from many other regions of the world.
Early prevention and control of dyslipidaemia is of paramount importance to reduce the risk of devel-
oping CVD.
Education of the public and healthcare professionals and developing preventive programs, FH regis-
tries and regional guidelines on dyslipidaemia are the keys to dyslipidaemia management in the ME
region.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular disease (CVD) is the leading cause of mortality
worldwide and to address this growing issue, the World Health
Organization and the World Heart Federation have suggested
strategies to accelerate the decline in the burden of CVDworldwide
[1]. The CVD-associated mortality rate in the Middle East (ME) is
one of the highest in the world [2]. In addition, studies such as the
Gulf Registry of Acute Coronary Events (Gulf RACE) and theartment, Sultan Qaboos Uni-
man.
i@gmail.com (K. Al Rasadi).
Ireland Ltd. This is an open accessinternational case-control analysis of risk factors for a ﬁrst
myocardial infarction (INTERHEART) have found that patients in
the ME who present with heart attacks are 10e12 years younger
than those in Western countries [3,4].
Dyslipidaemia is a recognized major risk factor leading to
atherosclerotic CVD and its treatment has been shown to reduce
the incidence of CVD morbidity and mortality [5e7].
Deﬁnition of dyslipidaemia is unclear due to the indiscriminate
use of different diagnostic criteria, which may result in inaccurate
interpretations, and lead to marked variations in the prevalence of
dyslipidaemia reported in different studies [8]. There are few
studies regarding the prevalence of dyslipidaemia in the ME
[9e12]. This review paper was developed by a panel of experts from
Iraq, Kuwait, Lebanon, Oman, Saudi Arabia and United Arabarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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of dyslipidaemia, to identify gaps in its management in the ME
region and to propose initiatives designed to reduce the burden of
dyslipidaemia in the region.
2. Materials and methods
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines were adhered to perform this
mini-review. No registered protocol exists for this review. The
article is based on presentations and discussions on the available
and relevant published studies that took place at an advisory board
meeting, which was funded by Sanoﬁ. The published studies
included randomized control trials, review articles and most recent
international guidelines on the diagnosis and treatment of dysli-
pidaemia, which were sourced from PubMed. The panel critically
analysed and discussed these articles at the meeting. The validity,
clinical relevance and applicability of the evidence in the ME were
discussed. Full text articles of the references that were discussed at
the meeting were sourced electronically, or via direct contact with
the authors.
2.1. Prevalence of dyslipidaemia worldwide
The prevalence of dyslipidaemia varies between different
countries depending on the population studied, geographic loca-
tion, socioeconomic development, gender, the presence of meta-
bolic disorders and genetic factors [13]. Additionally, different
diagnostic criteria are used to deﬁne dyslipidaemia, which can lead
tomarked variations in the prevalence of dyslipidaemia reported in
different studies [8]. Most of the reported studies on the prevalence
of dyslipidaemia are based on criteria used in the Adult Treatment
Panel III of the National Cholesterol Education Program (NCEP ATP
III) updated recommendations which deﬁnes dyslipidaemia as total
cholesterol (TC)  6.2 mmol/L (240 mg/dL), triglycerides
(TG) > 2.2 mmol/L (200mg/dL), low-density lipoprotein cholesterol
(LDL-C) > 4.1 mmol/L (160 mg/dL) and high-density lipoprotein
cholesterol (HDL-C) < 1.0 mmol/L (40 mg/dL) in men and
<1.2 mmol/L (50 mg/dL) in women [14] (Table 1). In the National
Health and Nutrition Examination Survey (NHANES), which was
conducted in 4275 in United State (US) population between 1999
and 2002, the estimated prevalence of dyslipidaemia was 52.9%
[15]. In the Multi-Ethnic Study of Atherosclerosis (MESA), which
was conducted in six American communities between 2000 andTable 1
Prevalence of dyslipidaemia in observational studies.
Study name (country) year N Age Gu
NHANESa (USA) 1999e2002 4275 45.4 ± 0.5 Up
MESAc (USA) 2000e2002 6814 45e84 Up
Canadian Health Measures Survey (Canada) 2007e2009 1701 20e79 TC
GEMCASd (Germany) 35,869 18e99 Eu
Brazilian Society of Cardiology (Brazil) 2011 1000 11e16 TC
Gulf RACE-2e (Arabian Gulf Countries) 2008e2009 7930 56 ± 17 Up
ACEf study (Africa and Middle East) 2011e2012 4378 46 ± 14 Up
a NHANES: National Health and Nutrition Examination Survey.
b NCEP ATP III guideline, Adult Treatment Panel III of the National Cholesterol Educati
c MESA: Multi-Ethnic Study of Atherosclerosis.
d GEMCAS, German Metabolic and Cardiovascular Risk Project.
e Gulf RACE-2, Gulf Registry of Acute Coronary Events-2.
f ACE, The Africa Middle East Cardiovascular Epidemiological.
g Updated NCEP ATP III guideline deﬁne dyslipidaemia as total cholesterol (TC)  6.2
poprotein cholesterol (LDL-C) > 4.1 mmol/L (160 mg/dL) and high-density lipoprotein ch
women.
h European guideline deﬁne dyslipidaemia as TC of below 4.9 mmol/L (190 mg/dL) and
patients with established CVD or diabetes mellitus (DM) of TC < 4.5 mmol/L (175 mg/dL2002 using the updated NCEPATP III criteria, the overall prevalence
of dyslipidaemiawas 29$3% [16]. Other studies, however, have used
different criteria. For example, in the Canadian Health Measures
Survey (2007e2009), the overall prevalence of dyslipidaemia was
45% and was deﬁned as TC/HDL-C ratio  5; LDL-C  4.9 mmol/L
(190 mg/dL) or taking lipid modifying medications [17]. In the
German Metabolic and Cardiovascular Risk Project (GEMCAS) [18],
the overall dyslipidaemia rate was 76% and was based on the Eu-
ropean guidelines, which recommend a TC of below 4.9 mmol/L
(190 mg/dL) and an LDL-C of below 3$0 mmol/L (115 mg/dL) for the
general population and goals for patients with established CVD or
diabetes mellitus (DM) of TC < 4.5 mmol/L (175 mg/dL) and LDL-
C < 2.5 mmol/L (100 mg/dL). The Brazilian Society of Cardiology
revised the deﬁnition of dyslipidaemia in adolescents in 2005 and
used more stringent cut-off values of TC > 4.3 mmol/L (170 mg/dL)
than those used previously by the NCEP of 5.1 mmol/L
(TC  200 mg/dL). The prevalence of dyslipidaemia in the Brazilian
adolescent based on this new deﬁnitionwas higher compared with
prevalence based on the NCEP deﬁnition (61% vs. 20.2%) [19].2.2. Prevalence of dyslipidaemia in the ME
There are few studies regarding the prevalence of dyslipidaemia
in theME [9e12]. Although the prevalence of dyslipidaemia inmost
of these studies was based on the updated NCEP ATP III different
cut-off values and ratios of lipid levels were used [14]. In the sys-
tematic review conducted by Moltagh and colleagues on the key
CVD risk factors in the ME from January 1980 to April 2005, the
prevalence of dyslipidaemia was not calculated because of marked
variations in the deﬁnition used in the different studies [20].
Another systematic review conducted by Aljefree and colleagues on
the CVD risk factors in adult population in the Gulf countries from
1990 to 2014 found that the overall prevalence of hyper-
cholesterolaemia (deﬁned as TC  5.1 mmol/L [200 mg/dL]) ranged
from 17% to 54·9% in males and 9% to 53·2% in females [10]. It is
worthy to mention that there was no consistent deﬁnition of dys-
lipidaemia used among the included studies. Alhyas and colleagues
conducted another systematic review of risk factors for DM in
studies from the Gulf countries between 1987 and 2010 [11]. In this
review, reported rates of dyslipidaemia ranged between 2.7 e
51.9%. The wide range of dyslipidaemia prevalence in these sys-
temic reviews was attributed to the different deﬁnitions and lipid
cut-off values used in the different studies. The Africa Middle East
Cardiovascular Epidemiological (ACE) study surveyed 4378idelines or cut off values Dyslipidaemia prevalence
dated NCEP ATP IIIb guidelineg 52.9%
dated NCEP ATP IIIb guideline 29.3%
/HDL-C ratio  5; LDL-C  4.9 mmol/L (190 mg/dL) 45%
ropean guidelinesh 76%
> 4.3 mmol/L (170 mg/dL) 61%
dated NCEP ATP III guideline 32.7%
dated NCEP ATP III guideline 70%
on Program.
mmol/L (240 mg/dL), triglycerides (TG) > 2.2 mmol/L (200 mg/dL), low-density li-
olesterol (HDL-C) < 1.0 mmol/L (40 mg/dL) in men and <1.2 mmol/L (50 mg/dL) in
an LDL-C of below 3.0 mmol/L (115 mg/dL) for the general population and goals for
) and LDL-C < 2.5 mmol/L (100 mg/dL).
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countries in the ME, including Saudi Arabia, UAE, and Kuwait) with
intermediate and high risk CVD status [12]. The overall prevalence
of dyslipidaemia in the ACE study was 70% and was deﬁned based
on the updated NCEP ATP III guideline (Table 1). There were also
other studies like the Gulf Registry of Acute Coronary Events (Gulf
RACE-1 and-2), and the INTERHEART study that also looked at the
prevalence of dyslipidaemia in theME [4,21,22]. In the INTERHEART
ME study which enrolled 1364 cases of ﬁrst acute myocardial
infarction and 1525 matching controls from eight ME countries
with the two most important and prevalent risk factors being
smoking and apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1)
ratio [4]. The overall dyslipidaemia prevalence which was deﬁned
by the quintiles of ApoB/A1 ratio was signiﬁcant for the top quin-
tiles in the cases than the controls (43.4 vs. 23.8; p < 0.0001) and
was more strongly associated with acute myocardial infarction
compared to the weaker association seen with the TC/HDL-C ratio
(odds ratio of 3.43 vs.1.19). On the other hand, the Gulf Race-1 was a
prospective study conducted in 2007 in 6704 acute coronary syn-
drome (ACS) patients from 64 hospitals in six ME countries
(Bahrain, Kuwait, Qatar, Oman, UAE, and Yemen) [21]. The preva-
lence of dyslipidaemia in this study was 32% and dyslipidaemiawas
deﬁnedwhen patients were known to have the risk factor andwere
already on lipid lowering drugs. The Gulf RACE-2, which was, a
prospective study conducted from October 2008 to June 2009 in 65
hospitals from six Arabian Gulf countries (Bahrain, Saudi Arabia,
Qatar, Oman, UAE, and Yemen), enrolled 7930 ACS patients with
30-day and one-year mortality follow-up [22]. In this study, the
prevalence of dyslipidaemia was 32.7%.
As observed from the previous studies, the prevalence of dys-
lipidaemia in the ME seems to be high, despite the wide range
variations between the different studies, which may be attributed
to the type of populations included in these studies. Nonetheless,
this fact also calls for an action to use a standardized deﬁnition for a
true and acceptable estimate of dyslipidaemiamagnitude in theME
region.
2.3. Existing gaps regarding dyslipidaemia management in the ME
region
2.3.1. Lack of standardized deﬁnition and management guidelines
for dyslipidaemia
The issue of lack of standardized deﬁnition of dyslipidaemia in
the ME region was highlighted in the previous section. In addition
to this issue, currently, there is no lipid guidelines developed for the
management of dyslipidaemia in the ME. Most of the ME countries
and regional societies depend on lipid guidelines developed by
international bodies [14,23e25]. Although, these guidelines are
very useful for the management of the general types of dyslipi-
daemia in the ME, other common types of dyslipidaemia in the
region related to DM, metabolic syndrome (MetS), and including
high levels of TG and low levels of HDL-C may need a position
statement from another lipid expert panels in the region.
2.3.2. Limited knowledge about familial hypercholesterolaemia
Familial hypercholesterolaemia (FH) is an inherited disorder,
characterized by an increase in the concentration of LDL-C in
plasma due to impaired hepatic clearance of LDL particles [26].
Mutations in the genes encoding the LDL receptor (LDL-R) [27], apo
B-100 [28], and proprotein convertase subtilisin/kexin type 9
(PCSK9) [29] are implicated in the autosomal dominant form of FH
while LDL-R adaptor protein 1 [30] is implicated in the autosomal
recessive form of FH. French Canadians, Ashkenazi Jews, Lebanese
and Dutch Afrikaners are at a higher risk for FH due to founder
mutations that result in an especially high prevalence ofheterozygous FH (HeFH) in these countries [31]. A high frequency of
the LDL-R p.Cys681Xmutation accounts for 81.5% of the FH patients
in the Lebanese population [32]. It is noteworthy that the frequency
of homozygous FH (HoFH) is more than ten-fold higher in Lebanon
than in other populations. This is likely attributable to a high
prevalence of HeFH among Lebanese people coupled with a high
incidence of consanguinity [33].
The lack of registries and cascade genetic screening in the ME
means that the overall prevalence of FH in the region is unknown.
FH-related mutations have been poorly reported in the ME when
compared to the situation in the Western World. A systematic re-
view to identify all FH-related mutations reported in ME and
Western populations identiﬁed only 57mutations in 17Middle East
and North Africa countries, compared with over 500 mutations in
three Western countries [34]. Recent studies, particularly from the
Netherlands, suggest that HoFH may affect as many as one in
160,000e300,000 people [35] and for theME, this prevalence could
be even higher because consanguineous marriages are more com-
mon than in the West [36].
There is evidence of both under-diagnosis and under treatment
of FH worldwide [35]. The under-diagnosis and under-treatment of
FH leave the risk of CVD in such people as much as 20-fold higher
than in those without FH. This creates a large economic burden
both worldwide and in the ME region [31]. Although statins are
widely available in the ME region, data regarding the optimal use of
statins with other combination therapies like ezetimibe in FH pa-
tients are not available. In addition, few centres for LDL-Apheresis
therapy are available across the ME region and this may compro-
mise the management of HoFH patients. Currently, new modalities
are approved by the United States Food and Drug Administration
for the treatment of HoFH with lometapide and HeFH with PCSK9-
ab (alirocumab, evolocumab) [37e39].
The high prevalence of CVD and low reporting of FH in the ME
highlight the need for establishing an FH registry and cascade ge-
netic screening as measures to reduce the burden of CVD in the
region, therefore a group of researchers are planning to start an FH
registry in the Gulf countries to address this issue. In addition,
another ME advisory panel has developed a recommendation for
identifying and treating patients with HoFH [40].
2.3.3. Knowledge and practice gaps in management of
dyslipidaemia
A general lack of awareness and lack of adherence to lipid
guidelines by physicians in the ME region result in a wide gap be-
tween guidelines and current daily practice in the management of
dyslipidaemia. Large percentage of patients with high and very
high CV risk is not achieving the recommended LDL-C treatment
goals [41,42]. In addition, many physicians in the region are hesitant
to use potent doses of statin in patients at high and very high CVD
risk [41,42]. In the Centralized pan-Middle East Survey on the
undertreatment of hypercholesterolaemia (CEPHEUS), which was
conducted in 5276 patients in six Arabian Gulf countries (Bahrain,
Saudi Arabia, Qatar, Oman, Kuwait and UAE) on lipid lowering drug
therapy, LDL-C goal was attained in 52% in the overall cohort [41]
according to the updated NCEP ATP III [43]. This study also
showed that physicians in the Gulf region seldom use high doses of
statins in high-risk patients. A total of 77$0% patients in this study
reported that they remained on the same dose of statin since it was
ﬁrst prescribed [41]. One of the possible reasons for this may be a
concern about the risk of adverse effects of high doses of statins.
This conclusion is supported by the observation that almost 50% of
the investigators agreed strongly that the patients become con-
cerned that their condition is more severe if their statins dose is up-
titrated [40]. Similar results, was observed in the Dyslipidaemia
International Study-Middle East (DYSIS-ME) study, which was an
K. Al Rasadi et al. / Atherosclerosis 252 (2016) 182e187 185international, cross-sectional, observational study, enrolled 2182
patients in the UAE, Saudi Arabia, Lebanon and Jordan who had
been on statin treatment for at least three months [42]. In this
study, 61.8% of all patients did not attain LDL-C target levels ac-
cording to the updated NCEP ATP III and approximately 32.1% of
very high-risk patients were receiving moderate dose statin po-
tency. Less substantial difference was observed in achieving LDL-C
targets among CEPHEUS-ME (52%) compared with CEPHEUS Pan-
European, Asian, Greece and South African (57.4, 49.1, 49.3, and
60.5%). On the other hand, more substantial difference was
observed in achieving LDL-C targets between DYSIS-ME (38.2%) and
DYSIS-Europe and Canada (51.8%) [44].
Similarly in the European Action on Secondary and Primary
Prevention by Intervention to Reduce Events (EUROASPIRE-III)
survey carried out in 2006e2007 in 12 European countries, TC
target was achieved in 30.6% among high-risk primary prevention
patients [45]. However, in the Lipid Treatment Assessment Project
(LTAP-2), which was carried out in more than 10,000 patients in 9
countries (United States, Canada, Mexico, Brazil, Spain, the
Netherlands, France, Taiwan, and Korea) between 2006 and 2007,
the overall LDL-C goal attainment ratewas 73% andwas higher than
previous reported studies [46]. The recent 2016 American College
of Cardiology (ACC) Expert Consensus panel emphasise on the
importance of using moderated to high intensity statin therapy in
the management of patients based on their Atherosclerotic Car-
diovascular Disease (ASCVD) Risk to control the LDL-C levels.
The panel also recommend using a non-statin therapy in pa-
tients with a less than anticipated response to statins, who are
unable to tolerate a less-than-recommended intensity of a statin, or
who are completely statin intolerant [47].
In addition, whilemany physicians are aware of the need to treat
patients aggressively to achieve recommended LDL-C goals, they
ignore the importance of optimizing other lipid therapeutic goals
like the non-HDL-C and apoB. This could be due to the lack of fa-
miliarity with international guidelines recommendation for these
target goals. In the CEPHEUS study, the recommended LDL-C target
was achieved in 25%, non-HDL-C in 36% and apoB in 38% of patients
in the highest risk cohort compared with achievement of LDL-C
targets, non-HDL-C targets and apoB targets of 46%, 58% and 51%,
respectively, in the high-risk group [48]. In patients with
TG  2.2 mmol/L (200 mg/dL), the recommended LDL-C target was
achieved in 16% and the recommended apoB target was achieved in
15% of patients in the highest risk group compared with 32%
achieving the LDL-C target and 22% achieving the apoB target in the
high-risk cohort.
Reduction of three major CVD risk factors (smoking prevalence,
serum cholesterol, and systolic blood pressure) in 34,525 men and
women aged 30e59 years who participated in the national FINRISK
studies between 1972 and 2012 in eastern Finland, was shown to be
signiﬁcantly related to the reduction in CAD mortality [49].
Therefore, is important to educate patients about dyslipidaemia as
a risk factor in the development of CVD and the need for it to be
treated in both primary and secondary prevention, especially in
those who have multiple risk factors (hypertension, DM, obesity,
smoking, and heart disease).
2.4. Recommendation of the expert panel for addressing the
management gaps in dyslipidaemia in the ME
2.4.1. Standardized deﬁnition and management guidelines for
dyslipidaemia
The panel recognizes the need to use a standardized deﬁnition
for dyslipidaemia to estimate its true magnitude in the region. The
panel recognizes that there are no speciﬁc regional cut-off values
for lipids and suggests using the updated NCEP guidelines cut-offvalues to deﬁne dyslipidaemia for the current time. In addition,
the panel recognizes the value of including non-HDL-C calculation
to this deﬁnition. The non-HDL-C (calculated as TC e HDL-C) is the
sum of all the atherogenic lipoproteins including the LDL-C, and
compared to the measured Apo B which makes it more cost-
effective lipid marker. An advantage of using non-HDL-C is that
there is no need for a fasting blood sample. Moreover, the non-HDL-
C is considered a better diagnostic and therapeutic marker than
LDL-C particularly in patients with DM and MetS [50].
The expert panel also recognizes the limitations of the current
international guidelines in highlighting the management of high
TG and low HDL-C in patients with DM and MetS, which is
considered very prevalent in the region. Therefore, a position
statement from another lipid expert panel in the region focusing on
the use of statin with combination therapies like ezetimibe,
ﬁbrates, niacin and Omega 3/Fish oils to treat patients with high TG
and low HDL-C in DM and MetS is needed. The discussion of this
position statement is beyond the scope of the current review and
will need another lipid expert panel to develop it in the future.
The expert panel recognizes the confusion about the term statin
intolerance and there is a need for a standardized deﬁnition [51].
The authors recommend the use of an alternate term such as
“maximum tolerated dose of statin”.
2.4.2. Reducing the gap of dyslipidaemia treatments in the ME
The expert panel recognizes the wide gap in achieving recom-
mended therapeutic targets for patients with high and very risk
CVD in the ME. Given the fact that there are no reported data on
showing increasing statin intolerance (mainly myalgia and
abnormal liver enzymes) when using moderate or high intensity
statin doses, the authors recommend using a maximum tolerated
dose of statin in the treatment of these patients. The authors also
recommend the use of a non-statin therapy in patients with a less
than anticipated response to statins, who are unable to tolerate a
less-than-recommended intensity of a statin, or who are
completely statin intolerant. Moreover, the authors recommend
that physicians should be educated about the importance of man-
aging other therapeutic target beyond the LDL-C like the non-HDL-
C.
2.4.3. Developing education and preventive programs for
dyslipidaemia and other CVD risk factors
The most effective method combatting dyslipidaemia and
reducing morbidity and mortality outcomes is by implementing
strong preventive programs for physicians and educational pro-
grams for patients.
The International Atherosclerosis Society and the Oman Society
of Lipid and Atherosclerosis organized a residential course - “Lipid
Metabolism and Cardiovascular Risk” in Muscat, Oman, 8e10
February 2015. This course aimed through a serial of lectures and
interactive practical workshops to increase the knowledge and
experience of early-to mid-career practicing clinicians from the
Middle East and North Africa region interested in the management
of lipid disorders. Such activity is planned to run on an annual basis
and will support the development of future lipidologists and
generate a network of lipid clinics designed to improve manage-
ment, to provide patient education and to promote research in
dyslipidaemia. http://www.athero.org/meetingHighlights.asp.
The authors also recognize the importance of optimizing the
treatment in this high-risk group by using moderate to high po-
tency doses of statin with ezetimibe and familiarising the treating
physicians with the new therapeutic modalities in the treatments
of FH like lometapide for HoFH and PCSK9-ab such as alirocumab
and evolocumab for HeFH.
The panel recognizes the importance of such programs and the
K. Al Rasadi et al. / Atherosclerosis 252 (2016) 182e187186need for funding support of such initiatives through governmental,
private sectors and the pharmaceutical industry.
2.4.4. Research and FH registry
There is a need for research in the ME region to obtain better
understanding of dyslipidaemia and to guide its management.
There is little information on statin intolerance in the ME region
and therefore more studies are required to quantify the condition.
The underreporting of FH mutations in the region where the con-
sanguinity rate is high indicates poor awareness of CVD genetic
risk. The authors therefore, highlight the importance to conduct
screening programs for early detection, to establish a registry and
to provide treatment options designed to reduce the risk of pre-
mature CVD due to FH in the ME. Screening for FH is challenging
since a precise organized effort is required to eliminate all sec-
ondary causes of hypercholesterolaemia. One approach is to
establish FH registry across the Gulf Cooperation Council and across
the ME region. A group of scientists from the region already met
and is currently working on starting the ﬁrst multinational FH
registry in the ME.
3. Conclusions
Education of the public and healthcare professionals, preventive
programs, FH registries and regional guidelines on dyslipidaemia
are the keys to dyslipidaemia management in the.ME region.
4. Conﬂict of interest and funding
All authors received honoraria and support to travel to the
expert meeting sponsored by Sanoﬁ, where the discussions for this
article took place. Sanoﬁ had no involvement in the process of
manuscript development and did not inﬂuence the content of this
manuscript in any manner.
K.A.R. received research support from Pﬁzer and acted as a
consultant or received honoraria from AstraZeneca, Pﬁzer, Sanoﬁ-
Regeneron and Aegerion. W.A. received honoraria from Menarini.
Astra Zeneca, Merck; Sanoﬁ; Boehringer Ingelheim; Novartis;
Abbott; Bayer; Servier, Takeda and was a member of advisory
boards for Advisory Boards Astra Zeneca, Bayer, Sanoﬁ and Merck.
M.A acted as a consultant (advisory board, lecturer) or received
honoraria from Amgen and Sanoﬁ-Regeneron and is involved in
anti-PCSK9 trials and studies with Amgen and with Regeneron-
Sanoﬁ. S.J received honoraria from Amgen as principal investi-
gator in a trial. P.B received research support fromMerck, Pﬁzer and
acted as a consultant or received honoraria from: Amgen, Astra-
Zeneca, Cerenis, CSL-Behring, Dezima Pharmaceuticals, Eli-Lilly,
Kowa, Merck, Novartis, Pﬁzer, Sanoﬁ-Regeneron.
The remaining authors had nothing to declare beyond the
sponsorship to the expert meeting by Sanoﬁ.
Acknowledgments
Medical writing and editorial support were provided by Ogilvy
Commonhealth Middle East and North Africa and funded by Sanoﬁ.
References
[1] S. Yusuf, D. Wood, J. Ralston, K.S. Reddy, The World Heart Federation's vision
for worldwide cardiovascular disease prevention, Lancet 386 (9991) (2015)
399e402.
[2] T.M. Ramahi, Cardiovascular disease in the Asia Middle East region: global
trends and local implications, Asia-Paciﬁc J. Public Health 22 (3 suppl) (2010)
83Se89S.
[3] M. Zubaid, W.A. Rashed, W. Almahmeed, J. Al-Lawati, K. Sulaiman, A. Al-
Motarreb, et al., Management and outcomes of middle eastern patients
admitted with acute coronary syndromes in the Gulf registry of acutecoronary events (Gulf RACE), Acta Cardiol. 64 (4) (2009) 439e446.
[4] A.A. Gehani, A.T. Al-Hinai, M. Zubaid, W. Almahmeed, M.M. Hasani,
A.H. Yusufali, et al., Association of risk factors with acute myocardial infarction
in Middle Eastern countries: the INTERHEART Middle East study, Eur. J. Prev.
Cardiol. 21 (4) (2014) 400e410.
[5] J. Costa, M. Borges, C. David, A.V. Carneiro, Efﬁcacy of lipid lowering drug
treatment for diabetic and non-diabetic patients: meta-analysis of rando-
mised controlled trials, BMJ. 332 (7550) (2006) 1115e1124.
[6] C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, E. Braunwald, Meta-anal-
ysis of cardiovascular outcomes trials comparing intensive versus moderate
statin therapy, J. Am. Coll. Cardiol. 48 (3) (2006) 438e445.
[7] B.G. Brown, K.H. Stukovsky, X.-Q. Zhao, Simultaneous low-density lipoprotein-
C lowering and high-density lipoprotein-C elevation for optimum cardiovas-
cular disease prevention with various drug classes, and their combinations: a
meta-analysis of 23 randomized lipid trials, Curr. Opin. Lipidol. 17 (6) (2006)
631e636.
[8] C.M. Tomeleri, E.R. Ronque, D.R. Silva, C.G.C. Júnior, R.A. Fernandes,
D.C. Teixeira, et al., Prevalence of dyslipidemia in adolescents: Comparison
between deﬁnitions, Rev. Port. Cardiol. English Ed. 34 (2) (2015) 103e109.
[9] M. Kheirandish, S. Asgari, M. Lotfaliany, M. Bozorgmanesh, N. Saadat,
M. Tohidi, et al., Secular trends in serum lipid levels of a Middle Eastern adult
population; 10 years follow up in Tehran lipid and glucose study, Lipids
Health Dis. 23 (2014) 13e20.
[10] N. Aljefree, F. Ahmed, Prevalence of cardiovascular disease and associated risk
factors among adult population in the Gulf region: a systematic review, Adv.
Public Health (2015) 2015.
[11] L. Alhyas, A. McKay, A. Balasanthiran, A. Majeed, Prevalences of overweight,
obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: sys-
tematic review, JRSM Short. Rep. 2 (7) (2011) 55.
[12] A.A. Alsheikh-Ali, M.I. Omar, F.J. Raal, W. Rashed, O. Hamoui, A. Kane, et al.,
Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa
Middle East Cardiovascular Epidemiological (ACE) Study, 2014.
[13] L. Zhang, Q. Qiao, Y. Dong, Ethnic Difference in Lipid Proﬁles, INTECH Open
Access Publisher, 2012.
[14] N.C.E.P.N.E. Panel, Third report of the National Cholesterol Education Program
(NCEP) expert panel on detection, evaluation, and treatment of high blood
cholesterol in adults (Adult Treatment Panel III) ﬁnal report, Circulation 106
(25) (2002) 3143.
[15] H.E. Bays, R.H. Chapman, K.M. Fox, S. Grandy, Comparison of self-reported
survey (SHIELD) versus NHANES data in estimating prevalence of dyslipide-
mia, Curr. Med. Res. Opin. 24 (4) (2008) 1179e1186.
[16] D.C. Goff, A.G. Bertoni, H. Kramer, D. Bonds, R.S. Blumenthal, M.Y. Tsai, et al.,
Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of
atherosclerosis (MESA) gender, ethnicity, and coronary artery calcium, Cir-
culation 113 (5) (2006) 647e656.
[17] M. Joffres, M. Shields, M.S. Tremblay, S.C. Gorber, Dyslipidemia prevalence,
treatment, control, and awareness in the Canadian Health measures survey,
Can. J. Public Health 104 (3) (2013) e252ee257.
[18] E. Steinhagen-Thiessen, P. Bramlage, C. L€osch, H. Hauner, H. Schunkert,
A. Vogt, et al., Dyslipidemia in primary careeprevalence, recognition, treat-
ment and control: data from the German Metabolic and Cardiovascular Risk
Project (GEMCAS), Cardiovasc Diabetol. 7 (1) (2008) 31.
[19] A.F. Sim~ao, D.B. Precoma, JPd Andrade, H. Correa Filho, J.F.K. Saraiva,
GMMd Oliveira, I cardiovascular prevention guideline of the Brazilian Society
of Cardiology-executive summary, Arq. Bras. Cardiol. 102 (5) (2014) 420e431.
[20] B. Motlagh, M. O'Donnell, S. Yusuf, Prevalence of cardiovascular risk factors in
the Middle East: a systematic review, Eur. J. Cardiovasc. Prev. Rehabil. 16 (3)
(2009) 268e280.
[21] A. El-Menyar, M. Zubaid, A. Shehab, B. Bulbanat, N. AlBustani, F. Alenezi, et al.,
Prevalence and impact of cardiovascular risk factors among patients pre-
senting with acute coronary syndrome in the middle East, Clin. Cardiol. 34 (1)
(2011) 51e58.
[22] K.F. AlHabib, K. Sulaiman, A. Al-Motarreb, W. Almahmeed, N. Asaad, H. Amin,
et al., Baseline characteristics, management practices, and long-term out-
comes of middle eastern patients in the second Gulf registry of acute coronary
events (Gulf RACE-2), Ann. Saudi Med. 32 (1) (2012) 9e18.
[23] Z. Reiner, A. Catapano, G. De Backer, I. Graham, M. Taskinen, O. Wiklund, et al.,
The task force for the management of dyslipidaemias of the European society
of Cardiology (ESC) and the European atherosclerosis society (EAS). ESC/EAS
guidelines for the management of dyslipidaemias, Eur. Heart J. 32 (14) (2011)
1769e1818.
[24] S.M. Grundy, H. Arai, P. Barter, T.P. Bersot, D.J. Betteridge, R. Carmena, et al., An
International Atherosclerosis Society Position Paper: global recommendations
for the management of dyslipidemia-full report, J. Clin. Lipidol. 8 (1) (2014)
29e60.
[25] T.A. Jacobson, M.K. Ito, K.C. Maki, C.E. Orringer, H.E. Bays, P.H. Jones, et al.,
National Lipid Association recommendations for patient-centered manage-
ment of dyslipidemia: Part 1eexecutive summary, J. Clin. Lipidol. 8 (5) (2014)
473e488.
[26] J.L. Goldstein, M.S. Brown, The LDL receptor, Arteriosclerosis, thrombosis,
Vasc. Biol. 29 (4) (2009) 431e438.
[27] M.S. Brown, J.L. Goldstein, Expression of the familial hypercholesterolemia
gene in heterozygotes: mechanism for a dominant disorder in man, Science
185 (4145) (1974) 61e63.
[28] T.L. Innerarity, K.H. Weisgraber, K.S. Arnold, R.W. Mahley, R.M. Krauss,
K. Al Rasadi et al. / Atherosclerosis 252 (2016) 182e187 187G.L. Vega, et al., Familial defective apolipoprotein B-100: low density lipo-
proteins with abnormal receptor binding, Proc. Natl. Acad. Sci. 84 (19) (1987)
6919e6923.
[29] M. Abifadel, M. Varret, J.-P. Rabes, D. Allard, K. Ouguerram, M. Devillers, et al.,
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat.
Genet. 34 (2) (2003) 154e156.
[30] C.K. Garcia, K. Wilund, M. Arca, G. Zuliani, R. Fellin, M. Maioli, et al., Autosomal
recessive hypercholesterolemia caused by mutations in a putative LDL re-
ceptor adaptor protein, Science 292 (5520) (2001) 1394e1398.
[31] J.G. Robinson, Management of familial hypercholesterolemia: a review of the
recommendations from the national lipid association expert panel on familial
hypercholesterolemia, J. Manag. Care Pharm. 19 (2) (2013) 139e149.
[32] M. Abifadel, J.P. Rabes, S. Jambart, G. Halaby, M.H. Gannage-Yared, A. Sarkis, et
al., The molecular basis of familial hypercholesterolemia in Lebanon: spec-
trum of LDLR mutations and role of PCSK9 as a modiﬁer gene, Hum. Mutat. 30
(7) (2009) E682eE691.
[33] A. Khachadurian, S. Uthman, Experiences with the homozygous cases of fa-
milial hypercholesterolemia, Ann. Nutr. Metab. 15 (1e2) (1973) 132e140.
[34] M.A. Bamimore, A. Zaid, Y. Banerjee, A. Al-Sarraf, M. Abifadel, N.G. Seidah, et
al., Familial hypercholesterolemia mutations in the Middle Eastern and North
African region: a need for a national registry, J. Clin. Lipidol. 9 (2) (2015)
187e194.
[35] B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, H.N. Ginsberg, L. Masana,
O.S. Descamps, et al., Familial hypercholesterolaemia is underdiagnosed and
undertreated in the general population: guidance for clinicians to prevent
coronary heart disease, Eur. heart J. 34 (45) (2013) 3478e3490.
[36] M. El-Hazmi, A. Al-Swailem, A. Warsy, A. Al-Swailem, R. Sulaimani, A. Al-
Meshari, Consanguinity among the Saudi Arabian population, J. Med. Genet.
32 (8) (1995) 623e626.
[37] M. Cuchel, E.A. Meagher, H. du Toit Theron, D.J. Blom, A.D. Marais, R.A. Hegele,
et al., Efﬁcacy and safety of a microsomal triglyceride transfer protein inhib-
itor in patients with homozygous familial hypercholesterolaemia: a single-
arm, open-label, phase 3 study, Lancet 381 (9860) (2013) 40e46.
[38] J.G. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, M. Averna, et al.,
Efﬁcacy and safety of alirocumab in reducing lipids and cardiovascular events,
N. Engl. J. Med. 372 (16) (2015) 1489e1499.
[39] M.S. Sabatine, R.P. Giugliano, S.D. Wiviott, F.J. Raal, D.J. Blom, J. Robinson, et al.,
Efﬁcacy and safety of evolocumab in reducing lipids and cardiovascular
events, N. Engl. J. Med. 372 (16) (2015) 1500e1509.
[40] A. Al-Ashwal, F. Alnouri, H. Sabbour, A. Al-Mahfouz, N. Al-Sayed, M. Razzaghy-
Azar, et al., Identiﬁcation and treatment of patients with homozygous familial
hypercholesterolaemia: information and recommendations from a Middle
East advisory panel, Curr. Vasc. Pharmacol. 13 (6) (2015) 759e770.
[41] M. Arafah, A.T. Al-Hinai, W. Al Mahmeed, K. Al-Rasadi, O. Al Tamimi, S. Al
Herz, et al., Centralized Pan-Middle East survey on the undertreatment ofhypercholesterolemia results from the CEPHEUS study in Arabian Gulf
countries, Angiology 65 (10) (2014) 919e926.
[42] S.N. Al Sifri, W. Almahmeed, S. Azar, O. Okkeh, P. Bramlage, C. Jünger, et al.,
Results of the Dyslipidemia International Study (DYSIS)-middle East: Clinical
Perspective on the Prevalence and Characteristics of Lipid Abnormalities in
the Setting of Chronic Statin Treatment, 2014.
[43] S.M. Grundy, J.I. Cleeman, C.N.B. Merz, H.B. Brewer, L.T. Clark,
D.B. Hunninghake, et al., Implications of recent clinical trials for the national
cholesterol education program adult treatment panel III guidelines, J. Am. Coll.
Cardiol. 44 (3) (2004) 720e732.
[44] A.K. Gitt, H. Drexel, J. Feely, J. Ferrieres, J.R. Gonzalez-Juanatey, K.K. Thomsen,
et al., Persistent lipid abnormalities in statin-treated patients and predictors of
LDL-cholesterol goal achievement in clinical practice in Europe and Canada,
Eur. J. Prev. Cardiol. 19 (2) (2012) 221e230.
[45] K. Kotseva, D. Wood, G. De Backer, D. De Bacquer, K. Py€or€al€a, Reiner Z, et al.,
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic
high-risk patients in general practice: cross-sectional survey in 12 European
countries, Eur. J. Cardiovasc. Prev. Rehabil. 17 (5) (2010) 530e540.
[46] D.D. Waters, C. Brotons, C.-W. Chiang, J. Ferrieres, J. Foody, J.W. Jukema, et al.,
Lipid treatment assessment project 2 a multinational survey to evaluate the
proportion of patients achieving low-density lipoprotein cholesterol Goals,
Circulation 120 (1) (2009) 28e34.
[47] C. AACC, ACC Expert Consensus Decision Pathway on the Role of Non-statin
Therapies for LDL-cholesterol Lowering in the Management of Atheroscle-
rotic Cardiovascular Disease Risk, 2016.
[48] K. Al-Rasadi, I. Al-Zakwani, W. Al Mahmeed, M. Arafah, A.T. Al-Hinai,
A. Shehab, et al., Therapeutic lipid target achievements among high and
highest risk patients: results from the CEPHEUS study in the Arabian Gulf,
Curr. Med. Res. Opin. 30 (12) (2014) 2429e2435.
[49] P. Jousilahti, T. Laatikainen, M. Peltonen, K. Borodulin, S. M€annist€o, A. Jula, et
al., Primary prevention and risk factor reduction in coronary heart disease
mortality among working aged men and women in eastern Finland over 40
years: population based observational study, bmj 352 (2016) i721.
[50] S.M. Boekholdt, B.J. Arsenault, S. Mora, T.R. Pedersen, J.C. LaRosa, P.J. Nestel, et
al., Association of LDL cholesterol, noneHDL cholesterol, and apolipoprotein B
levels with risk of cardiovascular events among patients treated with statins:
a meta-analysis, JAMA 307 (12) (2012) 1302e1309.
[51] M. Banach, M. Rizzo, P.P. Toth, M. Farnier, M.H. Davidson, K. Al-Rasadi, et al.,
Statin intolerance-an attempt at a uniﬁed deﬁnition. Position paper from an
International Lipid Expert Panel: this paper is also published in parallel in
Archives of Medical Science [Banach M, Rizzo M, Toth PP, et al. Statin
intolerance-an attempt at a uniﬁed deﬁnition. Position paper from an Inter-
national Lipid Expert Panel, Arch. Med. Sci. 11 (1) (2015) 1e23. Expert opinion
on drug safety. 2015(0):1-21.
